A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

26 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-29

Study Completion Date

2020-05-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to characterize the natural history of leukocyte chemotactic factor 2 amyloidotic (ALECT2) disease. In this observational study participants with ALECT2 disease will be enrolled. Participants, who have already reached end-stage renal disease (ESRD), will provide retrospective chart review data and biological specimens at baseline only. Other participants, in addition to retrospective chart review, will be followed prospectively.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Teclistamab-Daratumumab in AL Amyloidosis

NCT07110844

Amyloid Light-chain Amyloidosis

RECRUITING PHASE2

FKC288 for Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

NCT05978661

Light Chain Amyloidosis

RECRUITING PHASE1

Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study

NCT06455748

Amyloid Light-chain Amyloidosis

RECRUITING NA

Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis

NCT03000660

AL Amyloidosis

TERMINATED PHASE1

Daratumumab for Patients With Light Chain Amyloidosis

NCT06376214

Light Chain (AL) Amyloidosis

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Refer to www.studyALECT2.com

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amyloidosis Leukocyte Chemotactic Factor 2 Amyloidosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ALECT2 Disease

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and females, age 18 years or older;
* Renal biopsy-proven diagnosis of ALECT2;
* For patients with kidney disease that could be due to ALECT2, a renal biopsy may be obtained to confirm ALECT2 diagnosis.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No